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Abstract The folate derivatives folic acid (FA) and folinic
acid (FNA) decrease the in vivo and in vitro activities of
antifolate drugs in Plasmodium falciparum. However, the
effects of 5-methyl-tetrahydrofolate (5-Me-THF) and tetra-
hydrofolate (THF), the two dominant circulating folate
forms in humans, have not been explored yet. We have
investigated the effects of FA, FNA, 5-Me-THF, and THF
on the in vitro activity of the antimalarial antifolates
pyrimethamine and chlorcycloguanil and the anticancer
antifolates methotrexate (MTX), aminopterin, and trime-
trexate (TMX), against P. falciparum. The results indicate
that these anticancers are potent against P. falciparum, with
IC50<50 nM. 5-Me-THF does not significantly decrease the
activity of all tested drugs, and none of the tested folate
derivatives significantly decrease the activity of these
anticancers. Thus, malaria folate metabolism has features
different from those in human, and the exploitation of this
difference could lead to the discovery of new drugs to treat
malaria. For instance, the combination of 5-Me-THF with a
low dose of TMX could be used to treat malaria. In
addition, the safety of a low dose of MTX in the treatment
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Introduction
Antifolates inhibit the synthesis and conversion of folate
derivatives (FDs). Rapidly dividing cells such as cancer
cells, bacteria, or malaria parasites rely heavily on the
availability of folate to grow. Thus, blockade of synthesis of
these factors greatly affects cell division. This feature has
been exploited for the development of antifolate drugs. FDs
is a generic term that consists of ten different forms of
folate. The chemical structure of one of the FDs, folic acid
(FA), is shown in Fig. 1, and the role of FDs has been
discussed previously (Nzila et al. 2005a, b).
Fig. 1 Chemical structures of
folic acid and of the antifolate
drugs we analyzed
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Among all the FDs, 5-methyl-tetrahydrofolate (5-Me-
THF) is the most important one. It is the predominant FD in
mammals, representing 80–90% of the total folate content
(Belz and Nau 1998; Wagner 1995). The predominance of
5-Me-THF reflects its role as a cofactor in the conversion of
homocysteine to methionine, which in turn is the precursor
of S-adenosylmethionine, the methylation cofactor involved
in almost 100 reactions (Priest and Bunni 1995). Tetrahy-
drofolate (THF) is the second most represented FD in
mammals (10% of the total content); it is the product of the
main folate enzyme dihydrofolate reductase (DHFR; Nzila
et al. 2005a). The FDs FA and folinic acid (FNA) are used
clinically to lower the toxicity of antifolate drugs in the
treatment of cancer and rheumatoid arthritis (RA; Jackson
1999).
In Plasmodium falciparum parasites, studies have clearly
demonstrated that the addition of FA or FNA decreases the
activity of antifolate drugs, both in vitro and in vitro
(Kinyanjui et al. 1999; van Hensbroek et al. 1995).
Likewise, the lowering of the folate concentration in in
vitro culture medium enhances the activity of antifolate
antimalarial agents (Wang et al. 1997). By increasing the
folate derivative pools, the parasite can bypass the
inhibition of folate synthesis, leading to a decrease in
antifolate activity. However, the impact of the other FDs on
antifolate activity has not been explored in P. falciparum. In
the present paper, we explore the impact of 5-Me-THF and
THF along with FA and FNA on the standard antifolates
pyrimethamine (PM) and chlorcycloguanil (CCG) against
P. falciparum and the anticancer antifolates methotrexate
(MTX), aminopterin (AMP), and trimetrexate (TMX;
Fig. 1). We have included these anticancer drugs because
there have been indications that these agents are potent
against malaria parasite (Elslager et al. 1983; Fidock et al.
1998; Walter et al. 1991). Our study indicates that these
anticancer drugs alone (for MTX) or in combination with 5-
Me-THF (for TMX and AMP) could be used to treat
malaria. The potential of MTX as an antimalarial has led us
to explore the interaction of this antifolate with other
antimalarial drugs.
Materials and methods
FA, FNA, THF, 5-Me-THF, PM, dapsone (DDS), MTX,
AMP, chloroquine (CQ), mefloquine (MFQ), primaquine
(PRQ), quinine (QN), proguanil (PG), and probenecid
(PBN) were purchased from Sigma Chemical Co. (Poole,
UK). CCG was a gift from AstraZeneca (Cheshire, UK).
Amodiaquine (AQ), desethyl-amodiaquine (DEAQ), dihy-
droartemisinin (DHA), piperaquine (PQ), lumefantrine
(LM), pyronaridine (PRN), halofantrine (HLF), and chlor-
proguanil (CPG) were gifts from Professor Steve Ward,
Liverpool School of Tropical Medicine, Liverpool, UK.
Trimetrexate was a gift from Professor Andre Rosowsky,
Dana-Farber Cancer Institute, Boston, MA, USA.
Antimalarial activity was measured in the presence of
varying concentrations of each compound using radioiso-
topic incorporation (Sixsmith et al. 1984). Results were
expressed as the drug concentration required for 50%
inhibition of [3H]hypoxanthine incorporation into parasite
nucleic acid (IC50), using nonlinear regression analysis of
the dose–response curve. These IC50 values were deter-
mined in the presence or absence of increasing concen-
trations of folate derivatives. Two reference P. falciparum
laboratory isolates were tested: M24, a fully pyrimeth-
amine-sensitive isolate, and V1/S, a highly pyrimethamine-
resistant isolate. M24 carries a wild-type dhfr gene, but the
V1/S isolate has four mutations at codons 108, 51, 59, and
164 in its dhfr gene (Nzila et al. 2003). Cultures were
carried out in Roswell Park Memorial Institute (RPMI)
1640 (GIBCO BRL, UK) medium supplemented with 10%
(v/v) normal human serum, 25 mM bicarbonate, 2 mM
glutamine, 25-mM 4-(2-hydroxyethyl)-1-piperazine-ethane-
sulfonic acid buffer, and 3.6 nM para-aminobenzoic acid.
Human blood used to culture the parasites in vitro was
obtained from healthy subjects and washed three times with
RPMI culture medium nonsupplemented with serum.
Synergy Synergy analyses were carried out using V1/S
isolate in RPMI medium containing folic acid at physio-
logical concentration (23 nM). Synergy was assessed by
combining MTX with another drug in the following ratios:
1:0, 0.8:0.2, 0.6:0.4, 0.4:0.6, and 0.2:0.8. Synergy was
measured in vitro both geometrically by construction of
isobolograms (with a minimum of five coordinates) and
algebraically by calculating the sum of the minimum
fractional inhibitory concentration (FIC; Berenbaum
1978). Synergy is demonstrated when the FIC is <0.5. A
FIC value of >4.0 denotes an antagonistic effect and a FIC




We tested the in vitro activity of the anticancer agents
MTX, AMP, and TMX and the antimalarials PM and CCG
in the presence of increasing concentrations of FA, the
commonly used folate derivative, and THF, FNA, and 5-
Me-THF, using the multidrug-resistant V1/S and the fully
sensitive isolate M24. We used four folate concentrations:
0.023 μM, which is the physiological folate concentration
(normal value in the human body), and concentrations
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representing 10 (0.23 μM), 100 (2.3 μM) and 1,000
(23 μM) times the physiological concentration. The 2.3-
μM concentration is the highest concentration of folate that
can be achieved in vivo when high doses of folate
derivatives are administered (Barredo et al. 1999).
Table S1 shows the results of FA addition on the
antimalarial activity of PM and CCG using the multidrug-
resistant isolate V1/S. At the physiological FA concentra-
tion (0.023 μM), the IC50 values of the antimalarial
antifolates PM and CCG and the anticancer antifolates
MTX, AMP, and TMX were 875, 12, 31, 59, and 15 nM,
respectively. Increasing the concentration of FA to 0.23, 2.3
and 23 μM was associated with a significant decrease in
PM and CCG activity, and this decrease in activity was
proportional to the concentration of FA added to the
medium (Table S1). For instance, PM and CCG were
reduced by a factor of >45 in the presence of 23 μM of FA.
Surprisingly, however, the activities of MTX, AMP, and
TMX were virtually unchanged at 0.23 and 2.3 μM of FA,
and only a slight decrease was noticed at a concentration of
23 μM of FA, especially with TMX. Likewise, the same
trend was observed against the fully sensitive isolate M24.
At the physiological FA concentration, the IC50 values of
PM, CCG,MTX, AMP, and TMXwere 0.3, 0.22, 36, 48, and
4 nM, respectively (Table S2). PM and CCG activities were
decreased by 2.5- to 33-fold when 0.023, 2.3, and 2.3 μM
of FA were used, while the activities of AMP, MTX, and
TMX remained unchanged up to 23 μM of FA (Table S2).
We have also tested the effect of THF. The activities of
PM and CCG in the presence of THF at physiological folate
concentrations were 797 and 10 nM, respectively (Table S1).
These activities were decreased by between 5- and 100-fold
at the three highest folate concentrations tested. On the
other hand, MTX, AMP, and TMX activities remained
unchanged (24, 68, and 4 nM, respectively) at all THF
concentrations (Table S1). The same trend was observed
when M24 was used (Table S2). We tested the effect of
FNA, another form of folate that the parasite can salvage.
Similar to previous observations, FNA does not affect the
activity of MTX, AMP, and TMX, even at concentrations
500 times higher than the physiological folate concentra-
tion, unlike the effect on the antimalarials PM and CCG.
The use of 5-Me-THF yielded the most surprising results.
Indeed, this folate derivative, even when used at high
concentration, did not change the activity of any of the
tested drugs, including the antimalarials PM and CCG
(Tables S1 and S2).
Synergy between MTX and sulfa drug
The combination of a sulfa drug, an inhibitor of dihy-
dropteroate synthase (DHPS) and an inhibitor of DHFR,
produces a synergistic inhibition of the folate pathway. To
explore the mode of action of MTX further, we have tested
the synergistic properties of MTX in combination with the
DHPS inhibitor dapsone. All FICs were between 1 and
1.82, a clear indication that MTX does not synergize with
dapsone, while FICs of the combination CCG–DDS were
<0.5 (Table 1). Likewise, we did not observe any synergy
between TMX and DDS, and all FICs were in the range
1.2–1.5.
Probenecid effect
Lastly, we tested the effect of PBN on the activity of
anticancers MTX and TMX in P. falciparum. As part of our
previous work, we have demonstrated that PBN increases
the in vitro activity of antifolates, and this increase is
associated with a decrease in folate uptake (Nzila et al.
2003). We assessed the effect of PBN on the activity of
MTX and the results are summarized in Fig. 2. PBN alone
is a very weak antimalarial with a mean IC50>1,500 μM
against V1/S parasites. We have tested the effect of
noninhibitory concentrations of 50, 100, and 150 μM
PBN on the activity of MTX, TMX, and PM. The PM
IC50 against V1/S was 1,200 nM, and this IC50 decreased
by a factor between 2.5 and 5 as PBN concentration
increased from 50 to 150 μM; however, MTX and TMX
IC50 remained unchanged (at around 30 and 7 nM,
respectively). The data clearly show the absence of a PBN
effect on MTX and TMX in P. falciparum.
Synergy of MTX with other antimalarials
We also explored the in vitro interaction of MTX with
existing antimalarials by assessing its activity in the
presence of (1) inhibitors of malaria dihydrofolate reductase
(CCG and Walter Reed compound 99210); (2) triazine-
based compounds, synergizers of atovaquone (ATV; PG
and CPG), quinoline, and aryl amino-alcohol-related drugs
(CQ, PQ, LM, MFQ, HLF, DEAQ, QN, and PRQ); (3) the
antifolate anticancer TMX; (4) the sesquiterpene DHA; (5)
the benzonaphthyridine PRN; and (6) the naphthoquinone
derivative ATV. We used two synergistic combinations as
controls: CCG and DDS (see previous section) and ATV
and PG. Triazine compounds (PG) synergize with inhibitors
of electron transport to the cytochrome bc1 complex (ATV;
Jones and Ward 2002; Nzila 2006). The data are summa-
rized in Table 1. The combinations of CCG–DDS and
ATV–PG were synergistic, as one would predict, with total
FIC<0.5. All of the tested MTX combinations were
additive (except two), with the FIC value falling between
0.9 and 1.6, a clear indication that the activity of MTX is
neither decreased nor increased in the presence of any of
these drugs. However, the total FIC of the combination of
MTX with PNR was between 3.14 and 3.52, and two out
1230 Parasitol Res (2008) 102:1227–1234
of the four total FIC values of MTX with PQ (at ratios of
0.4:0.6 and 0.6:04) were 3.00 and 3.15. These values are
closer to 4, the cutoff point used to identify antagonistic
combinations, an indication that PNR and PQ may
antagonize MTX activity.
Discussion
Our data clearly indicate that malaria folate metabolism has
features different from those in human. Indeed, the
antimalarial activity of the anticancer drugs were not
decreased by FA, FNA, and THF. All of these forms of
folate increase the concentrations of dihydrofolate and THF,
the substrate and the product of DHFR reactions, respec-
tively. Under these conditions, one would expect the
activity of the inhibitors of DHFR to decrease. This is
what we observed with the standard antimalarial antifolates
PM and CCG but not with the anticancers MTX, AMP, and
TMX. Yet, evidence indicates that these anticancer drugs, at
least MTX, target malaria DHFR. Indeed, kinetics studies
Fig. 2 Effect of probenecid (PBN) on the activity of PM, MTX, and
TMX. Y axis represents the percentage decrease in IC50 in the presence
of PBN. One hundred percent (100%) represents the IC50 in the
absence of PBN. In the absence of PBN, the MTX, TMX, and PM
IC50 values were 30, 7, and 1,200 nM, respectively
Table 1 Activity of MTX in the presence of inhibitors of malaria dihydrofolate reductase (CCG and WR99210); inhibitors of dihydropteroate
synthase (DDS), triazine-based compounds, synergizers of atovaquone (PG and CPG), quinoline, and aryl amino-alcohol related drugs (CQ, PQ,
PRQ, LM, MFQ, HLF, DEAQ, and QN); the sesquiterpene dihydroartemisinin; the antifolate anticancer TMX; the benzonaphthyridine PRN and
the naphthoquinone derivative, ATV
Combination Drug ratio Score
1:1 0.8:0.2 0.6:0.4 0.4:0.6 0.2:0.8
Sum FIC
CCG–DDS 0.36±0.18 0.46±0.0 0.40±0.0 0.38±0.0 0.48±0.1 Synergistic
MTX–DDS 1.0±0.1 1.17±0.36 1.37±0.12 1.82±0.72 1.78±0.27 Additive
ATV–PG ND 0.25±0.0 0.22±0.1 0.24±0.0 0.28±0.0 Synergistic
MTX–PG 1.16±0.23 1.48±0.64 1.84±0 1.55±0.30 1.32±0.41 Additive
MTX–CPG ND 0.92±0.45 1.49±0.0 1.57±1.0 .98±0.0 Additive
MTX–CCG 1.1±0.3 1.09±0.29 1.06±0.16 1.18±0.12 1.81±0.81 Additive
MTX–WR99210 ND 1.10±0.3 1.20±0.3 1.37±0.4 1.40±0.5 Additive
MTX–CQ ND 1.40±0.34 1.48±0.44 1.08±0.18 1.17±0.0 Additive
MTX–DHA ND 1.47±0.2 1.33±0.7 1.20±0.30 0.84±0.22 Additive
MTX–LM 1.57±0.18 1.07±0.0 1.77±0.25 1.89±0.19 1.82±0.0 Additive
MTX–QN ND 1.47±0.41 1.73±0.24 1.56±0.31 1.36±0.0 Additive
MTX–TMX ND 1.0±0.1 1.33±0.0 1.35±0.0 1.43±0.0 Additive
MTX–PRQ ND 1.23±0.2 1.34±0.1 1.61±0.4 1.14±0.1 Additive
MTX–HLF ND 2.36±0.0 2.32±1.1 1.59±0.5 1.03±0.2 Additive
MTX–DEAQ ND 1.39±0.9 1.14±0.3 0.87±0.5 1.21±0.1 Additive
MTX–MFQ ND 1.90±0.7 1.67±0.8 1.40±0.9 1.38±1.2 Additive
MTX–ATV ND 1.26±0.2 1.63±0.0 1.15±0.3 1.58±0 Additive
MTX–PRN ND 3.52±1.2 3.24±1.6 3.14±0.4 3.36±1.0 Additive?
MTX–PQ ND 2.40±0.3 3.00±0.3 3.33±0.1 1.58±0.1 Additive?
CCG–DDS and ATV–PG were used as control synergistic combinations. Data are represented as the total fractional inhibitory concentration.
Synergy is demonstrated when the FIC is <0.5. A FIC value of >4.0 denotes an antagonistic effect and a FIC value between 0.5 and 4 indicates
either nonsynergistic or nonantagonistic interaction
CCG Chlorcycloguanil, DDS dapsone, MTX methotrexate, ATV atovaquone, PG proguanil, CPG chlorproguanil, WR99210 Walter Reed
compound 99210, CQ chloroquine, DHA dihydroartemisinin, LM lumefantrine, QN quinine, TMX trimetrexate, PRQ primaquine, HLF
halofantrine, DEAQ desethyl-amodiaquine, MFQ mefloquine, PRN pyronaridine
ti it of MTX in the pr sence of inhibitors of malaria
dihydrofolate reductase (CCG and WR99210); inhibitors of dihydr p-
teroate synthase (DDS), triazine-based compounds, synergizers of
atovaquone (PG and CPG), quinoline, and aryl amino-alcohol related
drugs (CQ, PQ, PRQ, LM, MFQ, HLF, DEAQ, and QN); th
sesquiterpene dihydroartemisinin; the antifolate anticancer TMX; the
benzonaphthyridine PRN and the nap thoquinone derivative, ATV
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on purified plasmodial DHFR have demonstrated that MTX
binds efficiently to P. falciparum and Plasmodium vivax
DHFR (Tahar et al. 2001; Toyoda et al. 1997), and
transfection of malaria parasite with human DHFR has
further demonstrated that the antimalarial activity of MTX
is primarily borne by the inhibition of DHFR (Fidock et al.
1998). Thus, we would expect that addition of folate
derivative would decrease the activity of these anticancer
drugs in P. falciparum. In addition, there is evidence that
MTX uses folate receptor–transporters to enter into the cell
(Wang et al. 2007); thus, the addition of FD would lower
MTX transport, leading to a decrease in MTX activity.
However, even at high concentrations, FDs do not decrease
MTX activity. Clearly, further studies are required to
understand the absence of the “folate effect” against these
anticancer antifolates.
The most unexpected effect was observed with 5-Me-
THF. The use of this folate derivative did not change the
activity of any of the drugs we tested, including the
antimalarials. 5-Me-THF is utilized to synthesize methio-
nine, and this reaction generates THF, the product of DHFR
reaction and this THF would modulate the activity of
antifolates as has been clearly demonstrated in mammalian
cells (Dudman et al. 1982; Etienne et al. 1993; Hilton et al.
1983; Mini et al. 1984; Reggev and Djerassi 1986). Our
data indicate that either 5-Me-THF is not transported into
the parasite cell or that the de novo methionine pathways
may not efficiently exist in the parasite. It is well
established that the parasite obtains its amino acid supply,
including methionine, from hemoglobin degradation. Thus,
under these conditions, the parasite may not need to
synthesize it de novo, though studies have indicated that
the methionine de novo pathway may exist in P. falcipa-
rum, (Asawamahasakda and Yuthavong 1993; Krungkrai et
al. 1989). However, because the parasite can obtain this
amino acid from hemoglobin degradation or exogenous
medium (Lew et al. 2003), this pathway can be of relative
importance, a possibility that has already been proffered
(Nzila et al. 2005a).
Because the addition of FA, FNA, and especially 5-Me-
THF does not decrease the activity of the anticancer drugs,
these folate derivatives could be used as adjuvants to
increase the antifolate therapeutic index. For instance, we
propose to use 5-Me-THF in combination with TMX to
treat malaria. This folate derivative would protect the host
against drug toxicity while it will not negate the antimalar-
ial activity of these anticancer drugs. For instance, the same
rational has been developed with the combination TMX +
FNA in the treatment of Pneumocystis jiroveci infection (an
opportunistic infection commonly found with human
immunodeficiency virus infection). TMX is a potent drug
against P. jiroveci and this microorganism cannot transport
folate derivatives; as a result, the combination of TMX +
FNA is as potent as TMX alone (Walzer et al. 1992). These
observations led scientists to propose the use of TMX +
FNA to treat P. jiroveci infection. This combination is safe,
and it is now the mainstay of P. jiroveci treatment (Amsden
et al. 1992; Fulton et al. 1995). In fact, TMX was
discovered as an antimalarial drug (Elslager et al. 1983)
but was developed as an anticancer because it is also active
against human cells. Because TMX is potent against the
malaria parasite (with IC50<15 nM), including highly PM-
resistant isolates (Table S1), and because TMX + 5-Me-
THF is as potent as TMX alone, thus, TMX + 5-Me-THF
could be used to treat malaria. It is interesting to note
that, based on the pharmacokinetics of TMX, the dose that
would be required to treat malaria would be lower than that
used in the treatment of cancer or P. jiroveci infection
(Marshall and DeLap 1994).
We also demonstrated that MTX is potent against P.
falciparum isolates with IC50<50 nM; thus, we propose this
drug could be used to treat malaria. MTX is used at high
doses up to 5–12 g/m2 per week (130–300 mg/kg) for
several weeks for the treatment of cancer (Barnhart et al.
2001). This dose can yield concentrations of >1,000 μM
MTX, which can have life-threatening toxicity (Barnhart et
al. 2001). On the other hand, a low dose of MTX (LD-
MTX; 0.1 to 0.35 mg/kg (7.5 to 25 mg per adult)) is used
for the treatment of RA on a chronic basis, for up to 5 years.
At this dose, MTX is safe and increasingly becoming the
mainstay in the treatment of RA in the Western world
(Borchers et al. 2004; Cronstein 2005; Ostor 2005; Suzuki
et al. 2005; Swierkot and Szechinski 2006). LD-MTX is also
becoming the drug of choice for the treatment of arthritis in
children and multiple sclerosis, and under this regime, MTX
is safe and well tolerated, (Niehues and Lankisch 2006;
Gray et al. 2004, 2006; Krishna Sumanth et al. 2007).
All this information has led us to propose the use of LD-
MTX in the treatment of malaria. The proof of the concept
that LD-MTX can be used to treat malaria in humans has
already been provided. Indeed, two small clinical trials
have demonstrated that doses as low as 2.5 mg per day for
3–5 days are effective to treat malaria infection in humans
(Sheehy and Dempsey 1970; Wildbolz 1973). However,
MTX has not come into widespread use because of
concerns over toxicity (Ferone 1971; Laing 1972). At the
time the aforementioned clinical trials were carried out
(which was in the 1970s), no information was available on
the safety of LD-MTX. LD-MTX has been widely used for
the treatment of arthritis since the 1980s, and its safety has
now been proven. Thus, this drug could be revived as an
antimalarial. Plans for clinical trials of this drug are under
way in our Unit.
We have also provided evidence that MTX does not
synergize with the DHPS inhibitor dapsone, yet all DHFR
inhibitors described as far synergize with inhibitor of DHPS
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(Nzila et al. 2005a) and that its activity is not increased by
the addition of PBN, a well-known potentiator of antifolate
activity (Hooijberg et al. 1999; Nzila et al. 2003). All these
observations support further that some features of antifolate
anticancers in P. falciparum are different from those found
in mammalian cells. To further study the mechanism of
action of MTX, we explored the in vitro interaction of
MTX with 16 existing antimalarials. We did not find any
synergistic combination; MTX has an additive effect with
all tested antimalarials, except with PNR and PQ. Thus,
MTX could be developed with any of the tested drugs as
combination therapy, except with PNR and PQ.
We have demonstrated that P. falciparum has unique
features as regards folate metabolism, and some of these
features could be exploited to develop antifolate anti-
cancers to treat malaria. For instance, TMX could be
combined with 5-Me-THF as an antimalarial, and the use
of MTX in the treatment of rheumatoid arthritis indicates
that this drug has the potential to become an antimalarial.
Plans to test MTX in vivo for the treatment of malaria are
under way.
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